Volixibat, also known as LUM-002, SHP-626, SAR-548304, is a medication under development as a possible treatment for nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). No other pharmacotherapy yet exists for NASH, so there is interest in whether volixibat can prove to be both safe and effective. Volixibat is an IBAT inhibitor, meaning that it blocks the function of the IBAT protein (ileal bile acid transporter), which is also called SLC10A2 (solute carrier family 10 member 2) or ASBT (apical sodium–bile acid transporter).
MedKoo Cat#: 125456
Name: Volixibat potassium monoethanolate monohydrate
CAS#: 1351444-01-3 (potassium monoethanolate monohydrate)
Chemical Formula: C40H58KN3O14S2
Exact Mass: 907.3000
Molecular Weight: 908.13
Elemental Analysis: C, 52.90; H, 6.44; K, 4.31; N, 4.63; O, 24.66; S, 7.06
The following data is based on the product molecular weight 908.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
